Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection
Metrics: PDF 1238 views | Full Text 2148 views | ?
Muntasir Billah1,2, Anisyah Ridiandries1,2, Usaid Allahwala2, Harshini Mudaliar1, Anthony Dona1, Stephen Hunyor1, Levon M. Khachigian3 and Ravinay Bhindi1,2
1Department of Cardiology, Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW, Australia
2Sydney Medical School Northern, University of Sydney, Sydney, NSW, Australia
3Vascular Biology and Translational Research, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
Muntasir Billah, email: firstname.lastname@example.org
Keywords: remote preconditioning; cardioprotection; myocardial infarction; ischemia-reperfusion; circulating mediators
Received: June 02, 2018 Accepted: December 10, 2018 Published: January 04, 2019
Acute myocardial infarction (AMI) is one of the leading causes of mortality and morbidity worldwide. There has been an extensive search for cardioprotective therapies to reduce myocardial ischemia-reperfusion (I/R) injury. Remote ischemic preconditioning (RIPC) is a phenomenon that relies on the body’s endogenous protective modalities against I/R injury. In RIPC, non-lethal brief I/R of one organ or tissue confers protection against subsequent lethal I/R injury in an organ remote to the briefly ischemic organ or tissue. Initially it was believed to be limited to direct myocardial protection, however it soon became apparent that RIPC applied to other organs such as kidney, liver, intestine, skeletal muscle can reduce myocardial infarct size. Intriguing discoveries have been made in extending the concept of RIPC to other organs than the heart. Over the years, the underlying mechanisms of RIPC have been widely sought and discussed. The involvement of blood-borne factors as mediators of RIPC has been suggested by a number of research groups. The main purpose of this review article is to summarize the possible circulating mediators of RIPC, and recent studies to establish the clinical efficacy of these mediators in cardioprotection from lethal I/R injury.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.